- Health
- SEE MORE
- classical
- general
- talk
- News
- Family
- Bürgerfunk
- pop
- Islam
- soul
- jazz
- Comedy
- humor
- wissenschaft
- opera
- baroque
- gesellschaft
- theater
- Local
- alternative
- electro
- rock
- rap
- lifestyle
- Music
- como
- RNE
- ballads
- greek
- Buddhism
- deportes
- christian
- Technology
- piano
- djs
- Dance
- dutch
- flamenco
- social
- hope
- christian rock
- academia
- afrique
- Business
- musique
- ελληνική-μουσική
- religion
- World radio
- Zarzuela
- travel
- World
- NFL
- media
- Art
- public
- Sports
- Gospel
- st.
- baptist
- Leisure
- Kids & Family
- musical
- club
- Culture
- Health & Fitness
- True Crime
- Fiction
- children
- Society & Culture
- TV & Film
- gold
- kunst
- música
- gay
- Natural
- a
- francais
- bach
- economics
- kultur
- evangelical
- tech
- Opinion
- Government
- gaming
- College
- technik
- History
- Jesus
- radio
- movies
- services
- Church
- podcast
- Education
- international
- Transportation
- Other
- kids
- podcasts
- philadelphia
- Noticias
- love
- sport
- Salud
- film
- and
- 4chan
- Disco
- Stories
- fashion
- Arts
- interviews
- hardstyle
- entertainment
- humour
- medieval
- literature
- alma
- Cultura
- video
- TV
- Science
- en
Treating Metastatic Colorectal Cancer with KRAS Biomarker With Dr. Mark Erlander Cardiff Oncology
Dr. Mark Erlander, CEO, Cardiff Oncology identifies the unmet needs of those suffering from metastatic colorectal cancer who have the oncogene KRAS mutation that hyper-drives the tumor growth.\xa0 Mark talks about the company's investigational drug, onvansertib that is being evaluated in metastatic colorectal cancer (mCRC), acute myeloid leukemia (AML), and metastatic castrate-resistant prostate cancer (mCRPC).\xa0 Onvansertib is a first-in-class, third-generation, oral and highly-selective inhibitor of PLK1, an enzyme that is over-expressed in most types of cancers. Onvansertib works synergistically in combination with approved chemotherapies and targeted therapeutics.
@CardiffOncology
#onvansertib #cancer #oncology #drugdevelopment #colorectalcancer #KRAS
\xa0